From: Changes in specialized blood vessels in lymph nodes and their role in cancer metastasis
HEV parameters | Clinical data | Relative risk | p | 95% Confidence interval |
---|---|---|---|---|
Total no. of HEV (A) | Overall Survival | 1.024 | 0.471 | 0.961 ~ 1.091 |
 | Disease Free Interval | 1.051 | 0.022 | 1.007 ~ 1.097 |
Total no. of HEV (A) and Disease Free Interval (as a Cohort) | Disease Free Interval | 1.051 | 0.023 | 1.007 ~ 1.096 |
Dilated HEV (B) | Overall Survival | 1.071 | 0.476 | 0.886 ~ 1.295 |
 | Disease Free Interval | 1.034 | 0.594 | 0.915 ~ 1.169 |
HEV with RBC within its lumen (C) | Overall Survival | 1.116 | 0.345 | 0.889 ~ 1.401 |
 | Disease Free Interval | 1.044 | 0.584 | 0.896 ~ 1.216 |
Ratio of dilated HEVs to the total no. of HEV(B/A) | Overall Survival | 1.078 | 0.982 | 0.002 ~ 638.23 |
 | Disease Free Interval | 10.10 | 0.450 | 0.001 ~ 39.89 |
Ratio of dilated HEVs with RBC to total no. HEV (C/A) | Overall Survival | 3.624 | 0.737 | 0.002 ~ 6634.42 |
 | Disease Free Interval | 4.67 | 0.643 | 0.001 ~ 145.83 |
Ratio of dilated HEVs with RBC within its lumen to total no. of dilated HEV (C/B) | Overall Survival | 17.884 | 0.171 | 0.287 ~ 1114.67 |
 | Disease Free Interval | 5.458 | 0.208 | 0.389 ~ 76.616 |